Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q3 2026 › vs Q2 2026
Rhythm Pharmaceuticals (RYTM) Q3 2026 vs Q2 2026 (quarter over quarter)
Rhythm Pharmaceuticals's revenue rose $20.9M (+29%) from $71.3M in Q2 2026 to $92.1M in Q3 2026.
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $92.1M | $71.3M | $20.9M | +29% |
| Net loss | $41.4M | $49.3M | −$7.9M | -16% |
| Costs & expenses | $133M | $121M | $12.9M | +11% |
| Operating costs | $131M | $120M | $11.6M | +10% |
| Interest & other, net | $1.5M | $302K | $1.2M | +393% |
| Income tax | $610K | $444K | $166K | +37% |
| Cost of revenue | $12.2M | $8.9M | $3.2M | +36% |
| Research & development | $52.5M | $43.4M | $9.1M | +21% |
| SG&A | $66.8M | $67.4M | −$696K | -1% |
| Operating cash sources | $41.4M | $49.3M | −$7.9M | -16% |
| Share-based compensation | $25.0M | $26.1M | −$1.0M | -4% |
| Working capital & other | $13.3M | $14.1M | −$808K | -6% |
| Cash used in operations | $3.1M | $9.2M | −$6.1M | -67% |
| Net loss absorbed | $41.4M | $49.3M | −$7.9M | -16% |
Questions
How much did Rhythm Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Rhythm Pharmaceuticals's revenue rose $20.9M (+29%) from $71.3M in Q2 2026 to $92.1M in Q3 2026.